Management of borderline ovarian tumours during pregnancy: Results of a French multi-centre study.


Journal

European journal of obstetrics, gynecology, and reproductive biology
ISSN: 1872-7654
Titre abrégé: Eur J Obstet Gynecol Reprod Biol
Pays: Ireland
ID NLM: 0375672

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 24 05 2020
revised: 05 10 2020
accepted: 10 11 2020
pubmed: 10 12 2020
medline: 15 5 2021
entrez: 9 12 2020
Statut: ppublish

Résumé

To assess the diagnostic and prognostic characteristics of borderline ovarian tumours (BOTs) detected during pregnancy, and to establish an inventory of French practices. A retrospective multi-centre case study of 14 patients treated for BOTs, diagnosed during pregnancy between 2005 and 2017, in five French pelvic cancerology expert centres, including data on clinical characteristics, histological tumour characteristics, surgical procedure, adjuvant treatments, follow-up and fertility. The mean age of patients was 29.3 [standard deviation (SD) 6.2] years. Most BOTs were diagnosed on ultrasonography in the first trimester (85.7 %), and most of these cases (78.5 %) also underwent magnetic resonance imaging to confirm the diagnosis (true positives 54.5 %). Most patients underwent surgery during pregnancy (57 %), with complete staging surgery in two cases (14.3 %). Laparoscopy was performed more frequently than other procedures (50 %), and unilateral adnexectomy was more common than cystectomy (57.5 %). Tumour size influenced the surgical approach significantly (mean size 7.5 cm for laparoscopy, 11.9 cm for laparoconversion, 14 cm for primary laparotomy; P = 0.08), but the type of resection did not. Most patients were initially diagnosed with International Federation of Gynecology and Obstetrics stage IA (92.8 %) tumours, but many were upstaged after complete restaging surgery (57.1 %). Most BOTs were serous (50 %), two cases had a micropapillary component (28.5 %), and one case had a micro-invasive implant. BOTs were bilateral in two cases (14.2 %). Mean follow-up was 31.4 (SD 14.8) months. Recurrent lesions occurred in two patients (14.2 %) and no deaths have been recorded to date among the study population. BOTs remain rare, but this study - despite its small sample size - supports the hypothesis that BOTs during pregnancy have potentially aggressive characteristics.

Identifiants

pubmed: 33296755
pii: S0301-2115(20)30744-2
doi: 10.1016/j.ejogrb.2020.11.033
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

412-418

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

M Zilliox (M)

Department of Gynaecology, University Hospital of Hautepierre, Strasbourg, France. Electronic address: marie.zilliox@chru-strasbourg.fr.

L Lecointre (L)

Department of Gynaecology, University Hospital of Hautepierre, Strasbourg, France; I-Cube UMR 7357 Science Laboratory, Strasbourg, France; IHU: Institute for Minimally Invasive Hybrid Image Guided Surgery, Strasbourg, France.

H Azais (H)

Department of Gynaecology, Pitié Salpetriere Hospital, Paris, France.

M Ballester (M)

Department of Gynaecology, Diaconesses Croix Saint Simon, Paris, France.

S Bendifallah (S)

Department of Gynaecology, Tenon Hospital, Paris, France.

P A Bolze (PA)

Department of Gynaecology, University Hospital South Lyon, Pierre-Bénite, France.

N Bourdel (N)

Department of Gynaecology, University Hospital of Clermont Ferrand, Clermont Ferrand, France.

A Bricou (A)

Department of Gynaecology, Diaconesses Croix Saint Simon, Paris, France.

G Canlorbe (G)

Department of Gynaecology, Pitié Salpetriere Hospital, Paris, France.

X Carcopino (X)

Department of Gynaecology, La Timone Hospital, Marseille, France.

P Chauvet (P)

Department of Gynaecology, University Hospital of Clermont Ferrand, Clermont Ferrand, France.

P Collinet (P)

Department of Gynaecology, Jeanne de Flandres Hospital, Lille, France.

C Coutant (C)

Centre de Lutte Contre le Cancer, Dijon, France.

Y Dabi (Y)

Department of Gynaecology, Tenon Hospital, Paris, France.

L Dion (L)

Department of Gynaecology, University South Hospital, Rennes, France.

T Gauthier (T)

Department of Gynaecology, University Hospital, Limoges, France.

O Graesslin (O)

Department of Gynaecology, University Hospital, Reims, France.

C Huchon (C)

Department of Gynaecology, Intercommunal Hospital of Poissy, Poissy, France.

M Koskas (M)

Department of Gynaecology, Bichat Hospital, Paris, France.

V Lavoue (V)

Department of Gynaecology, University South Hospital, Rennes, France.

M Mezzadri (M)

Department of Gynaecology, Lariboisière Hospital, Paris, France.

C Mimoun (C)

Department of Gynaecology, Lariboisière Hospital, Paris, France.

L Ouldamer (L)

Department of Gynaecology, University Hospital of Tours, Tours, France.

E Raimond (E)

Department of Gynaecology, University Hospital, Reims, France.

C Touboul (C)

Department of Gynaecology, Tenon Hospital, Paris, France.

M Lapointe (M)

Department of Gynaecology, University Hospital of Hautepierre, Strasbourg, France.

C Akladios (C)

Department of Gynaecology, University Hospital of Hautepierre, Strasbourg, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH